Compare Incyte Corporation (INCY) vs Lowe`s Companies Inc (LOW) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Incyte Corporation vs Lowe`s Companies Inc — how do they compare? Incyte Corporation trades at $121.06 (market cap $24.54B), while Lowe`s Companies Inc trades at $216.06 (market cap $124.06B). The key difference: Lowe`s Companies Inc is far larger — about 5.1× Incyte Corporation's market cap, and Lowe`s Companies Inc pays a 2.26% dividend while Incyte Corporation pays none. Which is the better fit depends on your goals.
| INCY | LOW | |
|---|---|---|
Market Cap | $24.54B | $124.06B |
Sector | Health | Consumer Cyclical |
52-Week High | $129.93 | $287.39 |
52-Week Low | $81.61 | $201.92 |
Enterprise Value | $20.04B | $165.81B |
Dividend Yield | — | 2.26% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Incyte Corporation (INCY) trades at $120.79, down 0.63% today, but maintains a bullish technical trend with strong fundamental performance. The stock is near its 52-week high, supported by robust earnings beats in Q1 and Q2 2026, with revenue growth accelerating to $5.14 billion in 2025. Recent news highlights regulatory approvals for Opzelura in the EU and a raised 2026 revenue outlook following a favorable CMS settlement.
The outlook remains positive given strong analyst consensus (52% buy ratings) and a $122.82 price target, though risks include reliance on key products and competitive pressures. Earnings momentum and institutional accumulation suggest further upside, but investors should monitor execution on growth initiatives.
Lowe's Companies (LOW) trades at $217.20, down 0.75% on the day, as the home improvement retailer prepares for its Q2 2026 earnings release on August 19. The stock shows strong fundamental performance with three consecutive quarterly EPS beats and positive cash flow generation of $840 million in 2025. Technical indicators suggest a bullish trend with moving averages supporting upward momentum, though RSI levels indicate potential overbought conditions near-term. Analyst consensus remains strongly positive with a $257.06 price target representing 18% upside potential.
Lowe's presents a compelling investment case with solid profitability metrics and consistent earnings outperformance, though investors face risks from declining revenue trends and elevated debt levels. The company's strategic investments in community programs and skilled trades training demonstrate long-term commitment, while near-term focus remains on Pro business growth and same-store sales improvement. Current valuation appears reasonable with P/E of 18.7 and P/S of 1.4, suggesting potential for appreciation if Q2 results meet or exceed expectations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →About Lowe`s Companies Inc
Lowe's is the second-largest home improvement retailer in the world, operating 1,969 stores and servicing around 230 dealer-owned stores throughout the United States and Canada. The firm's stores offer products and services for home decorating, maintenance, repair, and remodeling, with maintenance and repair accounting for two thirds of products sold. Lowe's targets retail do-it-yourself (around 75% of sales) and do-it-for-me customers as well as commercial and professional business clients (around 25% of sales). We estimate Lowe's captures a low-double-digit share of the domestic home improvement market, based on U.S. Census data and management's estimates for market size.
Read more on LOW →
